Key Highlights
- The analyst suggests that within the 7MM, there are approximately 3.4 million diagnosed prevalent cases of liver cirrhosis. Notably, the United States contributes approximately 60% of these cases, indicating a significant burden within the country compared to other nations in the 7MM.
- Liver cirrhosis cases are anticipated to increase due to factors like rising obesity rates and alcohol consumption. The absence of approved drugs highlights a critical gap in treatment options, underscoring the urgent need for effective pharmaceutical interventions in managing this debilitating condition.
- EU4 and the UK accounted for 24% of the total diagnosed prevalent cases of liver cirrhosis in the 7MM, which is anticipated to show a rise soon.
- As per the analyst's model, the etiology-specific diagnosed prevalent cases of liver cirrhosis were categorized into NASH, HCV, HBV, ALD, and PBC. The highest cases of cirrhosis were for ALD, with approximately 1 million cases, while the lowest cases were of PBC in 2022 among the 7MM countries.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Disease Understanding and Diagnostic Algorithm
Liver Cirrhosis Overview
Cirrhosis is the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, leading to portal hypertension and end-stage liver disease. In this late-stage liver disease, the healthy liver tissue is replaced with scar tissue, and the liver is permanently damaged, and scar tissue keeps the liver from working properly. Cirrhosis has many signs and symptoms, such as fatigue and severe itchy skin, and they may not appear until the liver is badly damaged. Causes include alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B.Liver Cirrhosis Diagnosis
The diagnosis of cirrhosis is usually based on the presence of a risk factor for cirrhosis, such as alcohol use or obesity, and is confirmed by physical examination, blood tests, and imaging. The doctor will ask about the person’s medical history and symptoms and perform a thorough physical examination to observe for clinical signs of the disease. The Child-Pugh scoring system (the Child-Pugh-Turcotte score) was designed to predict mortality in cirrhosis patients.Organizations like the European Association for the Study of the Liver (EASL), Japanese Society of Gastroenterology (JSGE), American Association for the Study of Liver Diseases (AASLD), and others have published criteria for diagnosing liver cirrhosis.
Liver Cirrhosis Epidemiology
As the market is derived using the patient-based model, the Liver Cirrhosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Liver Cirrhosis, and Etiology-specific diagnosed prevalent cases of Liver Cirrhosis, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per the analyst's estimations, the total diagnosed prevalent cases of Liver Cirrhosis in the 7MM comprised approximately 3.4 million cases in 2022 and are projected to increase during the forecast period.- The US showed the highest diagnosed prevalent population of liver cirrhosis compared to the other 7MM countries, with nearly 2 million cases in 2022. As per the analyst's estimates, the country alone accounts for nearly 61% of total diagnosed prevalent cases, for liver cirrhosis in the 7MM, followed by Japan, contributing 15% of all the liver cirrhosis cases.
- The etiology-specific distribution of diagnosed prevalent cases of liver cirrhosis showed NASH, HCV, HVB, ALD, and PBC comprised 28%, 27%, 11%, 33%, and 2% cases, respectively in the 7MM in 2022.
- EU4 and the UK accounted for around 0.8 million diagnosed prevalent cases of liver in 2022. Of these cases, Germany accounted for the highest number of diagnosed prevalent cases of liver cirrhosis among EU4 and the UK.
- Japan accounted for approximately 0.5 million cases of the total diagnosed prevalent cases of liver cirrhosis in the 7MM in 2022.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Liver Cirrhosis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from University of Florida Gainesville, Stanford University, Liver Unit, Hospital Clinic of Barcelona, Iwate Medical University, Leipzig University Hospital, and others.The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
- The report covers a segment of key events, an executive summary, descriptive overview of Liver Cirrhosis, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines.
- The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
- A detailed review of current challenges in establishing the diagnosis.
Liver Cirrhosis Report Insights
- Patient Population
- Country-wise Epidemiology Distribution
- Total Emergency Visits due to Cocaine
Liver Cirrhosis Report Key Strengths
- 12 years Forecast
- The 7MM Coverage
- Liver Cirrhosis Epidemiology Segmentation
Key Questions
Epidemiology Insights
- What are the disease risks, burdens, and unmet needs of Liver Cirrhosis? What will be the growth opportunities across the 7MM concerning the patient population of Liver Cirrhosis?
- What is the historical and forecasted Liver Cirrhosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Why do only limited patients appear for diagnosis?
- Which country is more prevalent for Liver Cirrhosis and why?
- What factors are affecting the diagnosis of the indication?
Reasons to Buy
- Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the Liver Cirrhosis prevalence cases in varying geographies over the coming years.
- A detailed overview of Severity, Gender, and Age-specific prevalence of Liver Cirrhosis.
- To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The Liver Cirrhosis Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.2. Out of all EU4 countries and the UK, which country had the highest population of Liver Cirrhosis cases in 2022?
The highest cases of Liver Cirrhosis was found in Germany among EU4 and the UK, in 2022.3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.4. Out of all 7MM countries, which country had the highest population of Liver Cirrhosis cases in 2022?
The highest cases of Liver Cirrhosis were found in the US among the 7MM in 2022.Table of Contents
1. Key Insights2. Report Introduction4. Epidemiology Forecast Methodology5. Executive Summary6. Key Events9. Patient Journey10. Key Opinion Leaders’ Views12. Publisher Capabilities13. Disclaimer14. About the Publisher
3. Inflammatory Myositis Epidemiology Overview at a Glance
7. Disease Background and Overview
8. Epidemiology and Patient Population
11. Appendix
List of Tables
List of Figures